Last updated: July 17, 2026
Boehringer Ingelheim v. Sun Pharmaceuticals (1:21-cv-00356): Litigation Summary, Claims at Issue, and Generic Entry Risk
Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) sued Sun Pharmaceutical Industries Limited (Sun) in a Hatch-Waxman patent case filed in 2021 under case number 1:21-cv-00356. The pleadings and case docket identify infringement allegations tied to a specific branded product and asserted U.S. patents, with the procedural posture centered on a generic or AB-rated applicant’s FDA filing and potential Paragraph IV exposure. The litigation record determines whether Sun’s proposed product can launch before patent expiry or through a carve-out, license, or settlement.
What is the case caption and docket for Boehringer Ingelheim v. Sun (1:21-cv-00356)?
Case: Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited
Court: U.S. District Court, case number 1:21-cv-00356
Year filed: 2021
Who are the parties and what are their roles
- Plaintiff: Boehringer Ingelheim Pharmaceuticals Inc. (BIPI)
- Defendant: Sun Pharmaceutical Industries Limited (Sun)
What claims typically drive this case type
This case fits the standard U.S. patent infringement framework used in Hatch-Waxman disputes:
- The brand-holder asserts one or more U.S. patents listed for the reference drug.
- The generic applicant’s ANDA (or related certification) triggers Paragraph IV allegations.
- The litigation seeks an injunction to block FDA approval and commercial launch during the asserted patent terms.
What patents are asserted in 1:21-cv-00356 and what infringement theories apply?
A complete and accurate patent-by-patent summary for 1:21-cv-00356 requires the specific asserted patent numbers and the asserted claims from the operative complaint. Without the complaint/claim list, any listing of patents would be speculative.
What a proper patent-issue breakdown must include
For each asserted patent, a litigation-grade summary normally maps:
- Patent number
- Patent title / scope (composition, formulation, method of use, manufacturing, stability, etc.)
- Asserted claim numbers
- Alleged infringement basis (literal infringement, equivalents, inducement/contributory where applicable)
- Validity challenges raised by defendant (anticipation, obviousness, lack of written description/enablement, indefiniteness, prosecution history estoppel, etc.)
Why this matters for generic-launch timing
The identity and claim scope of the asserted patents directly determine:
- Whether design-arounds exist (e.g., different salt form, different release profile, different dose regimen).
- Whether “carve-out” agreements are feasible.
- Whether an appellate stay or claim construction outcome accelerates or blocks launch.
When does exclusivity expire and how does that affect Sun’s generic entry risk?
Exclusivity and patent expiry dates are determined by:
- Orange Book listing(s) for the reference product
- Filing and approval dates (for regulatory exclusivities such as 5-year new chemical entity, 3-year new clinical investigation)
- Patent terms (including patent term adjustments)
- Any licensing or settlement carve-outs
A precise exclusivity and patent-expiry timeline cannot be produced without the FDA reference product name and the Orange Book listings asserted in the case.
What is the Orange Book status of the drug in Boehringer Ingelheim v. Sun?
Orange Book status requires:
- The reference listed drug (RLD) name
- Listed patents and their expiration dates
- The type of patent (drug substance, drug product, method of use)
- Whether Sun filed a Paragraph IV certification and which patents were certified
A litigation-grade “Orange Book status” summary cannot be completed without those identifiers.
How strong is Boehringer Ingelheim’s patent estate in this dispute?
Patent strength in these cases is assessed through:
- Remaining term on each asserted patent at filing
- Claim breadth under claim construction
- Technical likelihood of infringement (formulation/process compatibility)
- Validity vulnerability based on prior art proximity and claim support in the specification
Because 1:21-cv-00356 must be anchored to the specific asserted patents and claims, a strength score or claim-by-claim analysis cannot be stated accurately without the operative documents.
What procedural milestones occurred in 1:21-cv-00356?
Milestone categories that should be reflected in a litigation summary include:
- Complaint filing date and initial service
- Defendant’s answer and counterclaims (if any)
- Markman scheduling and claim construction orders
- Expert reports and Daubert rulings
- Summary judgment motions
- Trial date setting or case disposition events
- Injunction outcomes (if any) and any appellate posture
A precise chronology for 1:21-cv-00356 cannot be produced without docket events and dates.
Did Sun challenge validity under Paragraph IV, and what arguments were raised?
Paragraph IV validity challenges typically include:
- Anticipation by one or more prior art references
- Obviousness combinations
- Written description, enablement, best mode (as applicable)
- Indefiniteness
- Inequitable conduct (rare, but possible)
- Statutory subject matter eligibility defenses (depending on patent type)
A credible analysis requires the specific invalidity theories and supporting references cited in Sun’s invalidity contentions.
What settlement terms or consent judgments resolved (or narrowed) 1:21-cv-00356?
Settlement and consent judgment analysis requires:
- Existence of a settlement agreement
- Whether it includes a license, covenant not to sue, exclusivity carve-out, or a staged launch
- Payment terms (if public)
- Dismissal structure and scope
- Any admissions and ongoing obligations
Without settlement documents or docket entries, a terms summary cannot be made.
How do this case’s litigation outcomes affect potential generic launch scenarios?
Launch scenarios are driven by:
- Whether the brand obtained a preliminary injunction or entered final judgment
- Claim construction outcomes that narrow or broaden infringement elements
- The possibility of an agreed design-around or a licensing carve-out
- Whether the defendant wins at summary judgment or is forced to wait until patent expiry
A scenario tree cannot be reliably constructed without knowing:
- the asserted patents’ remaining terms,
- the case resolution posture,
- and any agreed launch conditions.
Does biosimilar-style risk apply, or is this a small-molecule ANDA case?
The caption indicates Sun is a pharma manufacturer in a U.S. patent infringement action. Whether the asserted drug is:
- a small molecule (ANDA typical), or
- a biologic (BLA and biosimilar pathway)
cannot be determined from the provided case identifier alone. The risk profile differs sharply between these pathways.
How does Boehringer Ingelheim’s strategy in 1:21-cv-00356 compare with other Boehringer vs. generic litigations?
A comparison needs:
- additional cases’ dossiers
- the pattern of asserted patent types (composition vs. method of use)
- claim construction approaches and win rates
No comparison can be supported without the specific patent estate and outcome for this case.
Key takeaways for business planning
- This is a U.S. patent infringement dispute between Boehringer Ingelheim Pharmaceuticals Inc. and Sun Pharmaceutical Industries Limited under 1:21-cv-00356.
- The litigation’s commercial impact depends on the specific asserted patents, the claim construction outcomes, and any settlement or injunction terms reflected in docket activity.
- A launch-impact model cannot be populated accurately without the Orange Book listing tied to the asserted patents and the operative claim list.
FAQs
What does case number 1:21-cv-00356 determine for FDA launch timing?
It determines whether the defendant’s FDA pathway is barred or delayed by judicial enforcement against the asserted patents, based on the Hatch-Waxman framework.
Is this case likely to involve Paragraph IV certifications?
Cases with this caption structure in Hatch-Waxman contexts typically involve Paragraph IV allegations tied to listed patents.
Can Sun design around the asserted patents?
Design-around feasibility depends on the claim scope of the asserted patents and outcomes of claim construction.
Do claim construction results usually decide cases like this?
Often, claim construction can narrow infringement/validity issues, but the actual decision depends on case-specific record and procedural posture.
What determines whether Boehringer wins an injunction?
Injunction eligibility depends on likelihood of infringement, validity, and irreparable harm standards under the court’s assessment and any pending appeal posture.
References
- Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Limited, case 1:21-cv-00356 (U.S. District Court docket).
